In total , @ patients were randomly assigned @:@ to receive intravenous temsirolimus @ mg once weekly ( n = @ ) or oral sorafenib @ mg twice per day ( n = @ ) , with stratification according to duration of prior sunitinib therapy ( or > @ days ) , prognostic risk , histology ( clear cell or non-clear cell ) , and nephrectomy status .